Drug major Zydus Cadila has received approval from the US health regulator to market Bupropion Hydrochloride extended-release tablets an anti-depressant medicine in the American market. Read more about anti-depressants Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Bupropion Hydrochloride Extended-release Tablets USP (XL) in the strength of 300 mg the company said in a statement. The drug falls in the anti-depressants segment it added. As per IMS sales data the estimated sales of Bupropion Hydrochloride Extended-release Tablets USP (XL) 300 mg was USD 255.9 million in 2013. The Ahmedabad-based group has
